Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | TDO2 | P48775 | 2/20 | 0.44 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322741 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL753104 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL29122982 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL29400420 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL29454486 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| Hydrochloric Acid SCHEMBL8015976 | 0.98 | MEN1 (0.58) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| Hydrochloric Acid SCHEMBL8015981 | 0.98 | MEN1 (0.58) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| Hydrochloric Acid SCHEMBL8015977 | 0.98 | MEN1 (0.58) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL24044801 | 0.84 | MEN1 (0.48) | MEN1KMT2ACYP1A2CYP3A4GRM1 | |
| SCHEMBL381133 | 0.84 | CYP1A2 (0.55) | MEN1KMT2ACYP1A2CYP3A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440139-A | Preparation method of clopidogrel sulfonate impurity | 廊坊市泽康医药科技有限公司 | 2020-07-24 | — | — | CN | claimed |
| US-6949658-B2 | Process for producing optically active α-amino acid and optically active α-amino acid amide | MITSUBISHI RAYON CO., LTD. (JP) | 2005-09-27 | — | — | US | claimed |
| US-20030171597-A1 | Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine | MITSUBISHI RAYON CO., LTD. (JP) | 2003-09-11 | — | — | US | claimed |
| EP-1300392-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-AMINO ACID AND OPTICALLY ACTIVE ALPHA-AMINO ACID AMIDE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-04-09 | — | — | EP | claimed |
| CN-117007695-A | Analysis method for determining content of potential genotoxic impurities in o-chlorophenylglycine | 苏州正济医药研究有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230279553-A1 | Method for Manufacturing Conductive Pattern-Provided Structure | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-09-07 | — | — | US | disclosed |
| CN-114507650-B | Leucine dehydrogenase mutant and application thereof in synthesis of (S) -o-chlorophenylglycine | 浙江工业大学 | 2023-09-05 | — | — | CN | disclosed |
| EP-4234758-A1 | METHOD FOR MANUFACTURING CONDUCTIVE PATTERN-PROVIDED STRUCTURE | Asahi Kasei Kabushiki Kaisha (JP) | 2023-08-30 | — | — | EP | disclosed |
| CN-115989341-A | Method for manufacturing structure with conductive pattern | 旭化成株式会社 | 2023-04-18 | — | — | CN | disclosed |
| CN-115968113-A | Method for manufacturing structure with conductive pattern, kit and system | 旭化成株式会社 | 2023-04-14 | — | — | CN | disclosed |
| CN-115888686-A | Cerium oxide @ carbon composite catalyst and synthesis method and application thereof | 安徽师范大学 | 2023-04-04 | — | — | CN | disclosed |
| US-20230028700-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | FU RUI (CA) | 2023-01-26 | — | — | US | disclosed |
| US-20040073057-A1 | Racemization of optically active 2-substituted phenyl glycine esters | USV. LTD. (CORPORATION OF INDIA) (IN) | 2004-04-15 | — | — | US | disclosed |
| US-20030171597-A1 | Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine | MITSUBISHI RAYON CO., LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-0971915-B1 | METHOD FOR PREPARING 2-THIENYLETHYLAMINE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2003-05-14 | — | — | EP | disclosed |
| EP-1300392-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-AMINO ACID AND OPTICALLY ACTIVE ALPHA-AMINO ACID AMIDE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6080875-A | REACTING A THIENYLGLYCIDIC DERIVATIVE WITH A PHENYLGLYCINE ESTER IN THE PRESENCE OF AN ALKALI METAL BOROHYDRIDE, DECYCLIZATION; PREPARING DRUGS FOR TREATING ANTI-PLATELET AGGREGATION AND ANTITHROMBOTIC ACTIVITIES | SANOFI-SYNTHELABO (FR) | 2000-06-27 | — | — | US | disclosed |
| EP-0971915-A1 | METHOD FOR PREPARING 2-THIENYLETHYLAMINE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998039322-A1 | METHOD FOR PREPARING 2-THIENYLETHYLAMINE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 1998-09-11 | — | — | WO | disclosed |
| US-5204469-A | PROCESS FOR THE PREPARATION OF AN N-PHENYLACETIC DERIVATIVE OF TETRAHYDROTHIENO(3,2-C)PYRIDINE AND ITS CHEMICAL INTERMEDIATE | SANOFI (FR) | 1993-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171597-A1 | Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine | AADAT, BCAT1, BCAT2 | MEN1 3310/4885KMT2A 902/4885CYP1A2 1627/4885 |
| US-20230028700-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | GMPS, GUCY1A2, GUCY1B2 | MEN1 3149/4885KMT2A 3227/4885CYP1A2 973/4885 |
| US-20040073057-A1 | Racemization of optically active 2-substituted phenyl glycine esters | GLO1, SLC6A5, SLC6A9 | MEN1 2599/4885KMT2A 4113/4885CYP1A2 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.